MediSynergics receives USPTO Notice of Allowance

MediSynergics reports that the company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ketamine derivative patent for the treatment of pain.

Dennis Godek, President and CEO, said the company is extremely pleased as several of the novel ketamine derivatives have proven to be more efficacious than ketamine in a murine inflammatory pain model.